Jump to content

Jeffrey A. Cohen

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Waacstats (talk | contribs) at 10:11, 27 December 2020 (stub sort). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Jeffrey A. Cohen
Born (1954-10-14) October 14, 1954 (age 70)

Jeffrey Alan Cohen (born October 14, 1954) is an American Neurologist specializing in Multiple Sclerosis and Director of Experimental Neurotherapeutics at the Cleveland Clinic Mellen Center for Multiple Sclerosis.

Education

B.A. - Connecticut College, New London, CT
M.D. - University of Chicago Pritzker School of Medicine Chicago, IL Postdoctoral training - Neurology - University of Pennsylvania

Notable contributions

  • Global Principal Investigator of the ACT (Avonex Combination Trial) clinical trial[1]
  • Global Principal Investigator of the TRANSFORMS Phase III trial of Fingolimod, a novel oral agent for use in treating Multiple Sclerosis, the primary results of which were presented at the American Academy of Neurology Annual Meeting in May 2009.[2]
  • Global Principal Investigator of the IMPACT trial, the first study to use the MS Functional Composite as the primary outcome measure in a clinical trial.[3]
  • Co-Editor of the textbook "Multiple Sclerosis Therapeutics", ISBN 1841845256[4]
  • Fellowship Director of the Mellen Center for MS National Multiple Sclerosis Society-supported Fellowship

References

  1. ^ ACT primary results manuscript
  2. ^ Medscape article on Fingolimod presentation AAN 2009
  3. ^ IMPACT primary results manuscript
  4. ^ Google Books page for Multiple Sclerosis Therapeutics


Flag of United StatesScientist icon

This biographical article related to a physician in the United States is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Jeffrey_A._Cohen&oldid=996562397"